MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Editas Medicine Cash and Cash Equivalents 2011-2026 | EDIT
Annual Cash and Cash Equivalents Editas Medicine
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 132 M | 124 M | 142 M | 207 M | 144 M | 238 M | 135 M | 147 M | 185 M | 143 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 238 M | 124 M | 160 M |
Quarterly Cash and Cash Equivalents Editas Medicine
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 166 M | 139 M | 139 M | 132 M | 95.8 M | 64.4 M | 69.2 M | 124 M | 82.5 M | 221 M | 129 M | 142 M | 215 M | 173 M | 215 M | 204 M | 264 M | 338 M | 355 M | 140 M | 140 M | 140 M | 140 M | 238 M | 238 M | 238 M | 238 M | 135 M | 135 M | 135 M | 135 M | 147 M | 147 M | 147 M | 147 M | 185 M | 185 M | 185 M | 185 M | 143 M | 143 M | 143 M | 143 M | 10.6 M | - | - | - | 2.01 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 355 M | 2.01 M | 161 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
466 M | $ 20.41 | -1.4 % | $ 2.57 B |  USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.79 | -6.51 % | $ 4.31 M |  China |
 |
Axsome Therapeutics
AXSM
|
323 M | $ 165.07 | -0.79 % | $ 8.21 B | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.76 | -1.7 % | $ 1.12 B |  Canada |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
322 M | $ 8.57 | -1.83 % | $ 1.4 B | Britain |
 |
Corvus Pharmaceuticals
CRVS
|
12.6 M | $ 18.11 | 1.23 % | $ 870 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
14.7 M | $ 26.36 | -1.82 % | $ 706 M | USA |
 |
Certara
CERT
|
189 M | $ 7.24 | 2.62 % | $ 1.16 B | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
19.3 M | $ 1.01 | -0.98 % | $ 74.1 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
709 M | $ 23.77 | -0.46 % | $ 2.91 B | USA |
 |
Agenus
AGEN
|
76.1 M | $ 3.27 | -2.09 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
89.1 M | $ 28.85 | -1.2 % | $ 1.67 B | USA |
 |
Champions Oncology
CSBR
|
9.78 M | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
143 M | $ 3.71 | -2.43 % | $ 116 M | France |
 |
Alector
ALEC
|
65.8 M | $ 2.13 | -3.39 % | $ 219 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
36.9 M | $ 4.22 | 1.32 % | $ 300 M | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
135 M | $ 14.3 | 2.66 % | $ 5.93 B |  Irlanda |
 |
AbbVie
ABBV
|
5.23 B | $ 233.44 | -0.33 % | $ 413 B | USA |